Scandinavian Biopharma receives 4.5 MSEK in funding from Vinnova
Scandinavian Biopharma via its subsidiary ETVAX receives 4.5 MSEK in funding from Vinnova for its project “One world one vaccine – to prevent ETEC diarrhea”.
Vaccination is one of the most effective and cost-effective medical interventions there are. Preventing disease if possible is something we all strive for. More than one million children under five die every year from diarrheal diseases. Traveler’s diarrhea is the same disease, and is also the most common infectious disease among travelers to tropical countries.
Our vision is to successfully develop a vaccine that could save hundred thousands of lives in the Third World, but also can save the holiday for millions of travelers, says Björn Sjöstrand, CEO of Scandinavian Biopharma. Today there is no ETEC vaccine available to address these unmet needs.
About Scandinavian Biopharma
Scandinavian Biopharma is one of few Swedish research based biotech companies. The company is also a leading distributor of vaccines and immunoglobulin’s to the Nordic market.
We develop together with the American global health non-profit organization, PATH Vaccine Solutions and researchers at the University of Gothenburg, a new travelers’ diarrhea vaccine, an oral ETEC vaccine.
A recently conducted clinical Phase I study showed impressive results where all primary endpoints were exceeded. In several clinical trials, the vaccine has been proven safe and shown a much better ability to activate the immune system than expected. A proof that we are on the right path, that our vaccine is of very high standard and with the potential to safe lives in the Third World, is that we are supported by PATH, an important partner of the Bill and Melinda Gates Foundation for the development of new vaccines in the field of diarrheal diseases for developing countries.
